Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement

Core Insights - Spartan Capital Securities LLC successfully completed a private placement for Lipella Pharmaceuticals Inc., raising $1,722,000 through the sale of up to 6,000,000 Series B non-voting convertible preferred stock [1][2][3] Company Overview - Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on addressing significant unmet medical needs with safe and effective therapies [2][3] - Jonathan Kaufman, PhD, serves as the CEO of Lipella Pharmaceuticals, leading the company's efforts in advancing its clinical pipeline [2] Transaction Details - The private placement closed on December 16, 2024, and the proceeds will support Lipella's clinical pipeline and general corporate purposes [2] - Spartan Capital Securities acted as the sole placement agent, highlighting its role in driving impactful investment opportunities [3] Legal and Compliance - Further details regarding the transaction will be available in Lipella's Form 8-K, which will be filed with the U.S. Securities and Exchange Commission [4] - The common shares and related warrants have not been registered under the Securities Act of 1933, and may not be offered or sold in the U.S. without registration or an applicable exemption [5]